{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T05:27:12Z","timestamp":1794806832229,"version":"4.9.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["europeanneuropsychopharmacology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.euroneuro.2013.01.001","type":"journal-article","created":{"date-parts":[[2013,1,30]],"date-time":"2013-01-30T11:46:09Z","timestamp":1359546369000},"page":"1551-1560","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Acute anxiolytic effects of quetiapine during virtual reality exposure\u2014A double-blind placebo-controlled trial in patients with specific phobia"],"prefix":"10.1016","volume":"23","author":[{"given":"Julia","family":"Diemer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Domschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"M\u00fchlberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernward","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxim","family":"Zavorotnyy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swantje","family":"Notzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Silling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Arolt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Zwanzger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2013.01.001_bib1","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2000"},{"key":"10.1016\/j.euroneuro.2013.01.001_bib2","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1017\/S1461145709990423","article-title":"Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study","volume":"13","author":"Bandelow","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2013.01.001_bib3","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1080\/15622970802465807","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders\u2014first revision","volume":"9","author":"Bandelow","year":"2008","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.01.001_bib4","series-title":"Anxiety and Its Disorders: The Nature and Treatment of Anxiety and Panic","author":"Barlow","year":"2002"},{"key":"10.1016\/j.euroneuro.2013.01.001_bib5","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/026988110201600412","article-title":"Efficacy of olanzapine in social anxiety disorder: a pilot study","volume":"16","author":"Barnett","year":"2002","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2013.01.001_bib6","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1037\/0022-006X.56.6.893","article-title":"An inventory for measuring clinical anxiety: psychometric properties","volume":"56","author":"Beck","year":"1988","journal-title":"J. Consult. Clin. Psychol."},{"key":"10.1016\/j.euroneuro.2013.01.001_bib7","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1038\/sj.npp.1300542","article-title":"The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes","volume":"29","author":"Bilder","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2013.01.001_bib8","doi-asserted-by":"crossref","unstructured":"Bj\u00f6rkholm, C., Jardemark, K., Marcus, M.M., Malmerfelt, A., et al. Role of concomitant inhibition of the norepinephrine transporter for the antipsychotic effect of quetiapine. Eur. Neuropsychopharmacol. 10.1016\/j.euroneuro.2012.05.012, in press.","DOI":"10.1016\/j.euroneuro.2012.05.012"},{"key":"10.1016\/j.euroneuro.2013.01.001_bib9","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1176\/appi.ajp.162.7.1351","article-title":"A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression","volume":"162","author":"Calabrese","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.01.001_bib10","doi-asserted-by":"crossref","first-page":"942","DOI":"10.4088\/JCP.09m05731blu","article-title":"Becoming the center of attention in social anxiety disorder: startle reactivity to a virtual audience during speech anticipation","volume":"72","author":"Cornwell","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.01.001_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008120.pub2","article-title":"Second-generation antipsychotics for anxiety disorders","volume":"12","author":"Depping","year":"2010","journal-title":"Cochrane Database Syst. Rev. (Online)"},{"issue":"Suppl. 2","key":"10.1016\/j.euroneuro.2013.01.001_bib12","doi-asserted-by":"crossref","first-page":"S127","DOI":"10.1007\/s00406-010-0143-9","article-title":"Therapy-refractory panic: current research areas as possible perspectives in the treatment of anxiety","volume":"260","author":"Diemer","year":"2010","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.euroneuro.2013.01.001_bib13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0165-1781(87)90002-3","article-title":"Measurement of lactate-induced panic and anxiety","volume":"20","author":"Dillon","year":"1987","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2013.01.001_bib14","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.neuroimage.2012.02.039","article-title":"Catechol-O-methyltransferase gene variation: impact on amygdala response to aversive stimuli","volume":"60","author":"Domschke","year":"2012","journal-title":"Neuroimage"},{"key":"10.1016\/j.euroneuro.2013.01.001_bib15","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1017\/S1461145705005869","article-title":"Association of the functional -1019C\/G 5-HT1A polymorphism with prefrontal cortex and amygdala activation measured with 3T fMRI in panic disorder","volume":"9","author":"Domschke","year":"2006","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"5","key":"10.1016\/j.euroneuro.2013.01.001_bib16","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/ajmg.b.30494","article-title":"Meta-analysis of COMT val158met in panic disorder: ethnic heterogeneity and gender specificity","volume":"144B","author":"Domschke","year":"2007","journal-title":"Am. J. Med. Genet. Pt. B: Neuropsychiatr. Genet."},{"key":"10.1016\/j.euroneuro.2013.01.001_bib17","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1017\/S146114570400416X","article-title":"Association of the functional V158M catechol-O-methyltransferase polymorphism with panic disorder in women","volume":"7","author":"Domschke","year":"2004","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2013.01.001_bib18","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.janxdis.2008.12.004","article-title":"Effect of quetiapine vs. placebo on response to two virtual public speaking exposures in individuals with social phobia","volume":"23","author":"Donahue","year":"2009","journal-title":"J. Anxiety Disord."},{"key":"10.1016\/j.euroneuro.2013.01.001_bib19","series-title":"Structured Clinical Interview for DSM-IV Axis I Disorders\u2014Patient Edition (SCIDI\/P, Version 2.0)","author":"First","year":"1996"},{"key":"10.1016\/j.euroneuro.2013.01.001_bib20","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jad.2009.12.031","article-title":"Anxiogenic properties of a computer simulation for panic disorder with agoraphobia","volume":"125","author":"Freire","year":"2010","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2013.01.001_bib21","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.4088\/JCP.v67n0902","article-title":"Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review","volume":"67","author":"Gao","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.01.001_bib22","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0893-133X(95)00147-6","article-title":"Symptoms essential to the experience of sodium lactate-induced panic","volume":"14","author":"Goetz","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2013.01.001_bib23","doi-asserted-by":"crossref","first-page":"S202","DOI":"10.1016\/j.eurpsy.2008.01.325","article-title":"Preclinical mechanisms for the broad spectrum of antipsychotic, antidepressant and mood stabilizing properties of Seroquel\u00ae","volume":"Suppl. 2","author":"Goldstein","year":"2008","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.01.001_bib24","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0006-3223(01)01322-1","article-title":"Evidence for a susceptibility locus for panic disorder near the catechol-O-methyltransferase gene on chromosome 22","volume":"51","author":"Hamilton","year":"2002","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.01.001_bib25","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.biopsych.2008.03.014","article-title":"Catechol-O-methyltransferase contributes to genetic susceptibility shared among anxiety spectrum phenotypes","volume":"64","author":"Hettema","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.01.001_bib26","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.cpr.2007.04.009","article-title":"Cognitive processes during fear acquisition and extinction in animals and humans: implications for exposure therapy of anxiety disorders","volume":"28","author":"Hofmann","year":"2008","journal-title":"Clin. Psychol. Rev."},{"key":"10.1016\/j.euroneuro.2013.01.001_bib27","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0006-8993(02)03570-9","article-title":"Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism","volume":"956","author":"Ichikawa","year":"2002","journal-title":"Brain Res."},{"key":"10.1016\/j.euroneuro.2013.01.001_bib28","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1038\/sj.npp.1301646","article-title":"N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity","volume":"33","author":"Jensen","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2013.01.001_bib29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/YIC.0b013e32833e34d9","article-title":"Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial","volume":"26","author":"Katzman","year":"2011","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2013.01.001_bib30","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1001\/archpsyc.62.6.617","article-title":"Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey replication","volume":"62","author":"Kessler","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.01.001_bib31","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1111\/j.1360-0443.2011.03563.x","article-title":"Benzodiazepines revisited\u2014will we ever learn?","volume":"106","author":"Lader","year":"2011","journal-title":"Addiction"},{"key":"10.1016\/j.euroneuro.2013.01.001_bib32","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.neulet.2004.11.063","article-title":"Norepinephrine transporter (NET) promoter and 5\u2032-UTR polymorphisms: association analysis in panic disorder","volume":"377","author":"Lee","year":"2005","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.euroneuro.2013.01.001_bib33","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1471-244X-10-99","article-title":"The COMTval158met polymorphism is associated with symptom relief during exposure-based cognitive-behavioral treatment in panic disorder","volume":"10","author":"Lonsdorf","year":"2010","journal-title":"BMC Psychiatry"},{"issue":"Suppl. 4","key":"10.1016\/j.euroneuro.2013.01.001_bib34","doi-asserted-by":"crossref","first-page":"S399","DOI":"10.1016\/S0924-977X(07)70596-5","article-title":"Anxiolytic effects of quetiapine in rat punished responding: Mechanism of action and the role of D2 antagonism","volume":"17","author":"Maciag","year":"2007","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2013.01.001_bib35","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2011.1360","article-title":"Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis","volume":"306","author":"Maher","year":"2011","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.euroneuro.2013.01.001_bib36","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1176\/appi.ajp.161.9.1703","article-title":"Association between catechol-O-methyltransferase and phobic anxiety","volume":"161","author":"McGrath","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.01.001_bib37","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1517\/14656566.8.9.1211","article-title":"A preclinical and clinical rationale for quetiapine in mood syndromes","volume":"8","author":"McIntyre","year":"2007","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.euroneuro.2013.01.001_bib38","series-title":"Profile of Mood States Manual (Rev.)","author":"McNair","year":"1992"},{"key":"10.1016\/j.euroneuro.2013.01.001_bib39","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/YIC.0b013e32834d9f49","article-title":"Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled study","volume":"27","author":"Merideth","year":"2012","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2013.01.001_bib40","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1026\/1616-3443.34.2.133","article-title":"Biocyberpsychologie: subjektive und physiologische Reaktionen von Flugphobikern und Gesunden bei Exposition mit virtuellen Fl\u00fcgen","volume":"34","author":"M\u00fchlberger","year":"2005","journal-title":"Z. Klin. Psychol. Psychother.: Forsch. Prax."},{"key":"10.1016\/j.euroneuro.2013.01.001_bib41","first-page":"147","article-title":"A virtual reality avoidance test (VR-BAT) for the assessment of spider phobia","volume":"1","author":"M\u00fchlberger","year":"2008","journal-title":"J. Cyberther. Rehabil."},{"key":"10.1016\/j.euroneuro.2013.01.001_bib42","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1468-1331.2011.03590.x","article-title":"The economic cost of brain disorders in Europe","volume":"19","author":"Olesen","year":"2012","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.euroneuro.2013.01.001_bib43","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.biopsych.2005.07.005","article-title":"Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study","volume":"59","author":"Pollack","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.01.001_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0005-7967(86)90143-9","article-title":"Anxiety sensitivity, anxiety frequency and the prediction of fearfulness","volume":"24","author":"Reiss","year":"1986","journal-title":"Behav. Res. Ther."},{"key":"10.1016\/j.euroneuro.2013.01.001_bib45","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1176\/jnp.8.4.383","article-title":"Anxiety and Parkinson's disease","volume":"8","author":"Richard","year":"1996","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"10.1016\/j.euroneuro.2013.01.001_bib46","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1089\/109493103769710497","article-title":"Anxiety and presence during VR immersion: a comparative study of the reactions of phobic and non-phobic participants in therapeutic virtual environments derived from computer games","volume":"6","author":"Robillard","year":"2003","journal-title":"CyberPsychol. Behav."},{"key":"10.1016\/j.euroneuro.2013.01.001_bib47","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1026\/\/1616-3443.31.2.110","article-title":"Ein Fragebogen zur Erfassung der Ekelempfindlichkeit (FEE)","volume":"31","author":"Schienle","year":"2002","journal-title":"Z. Klin. Psychol. Psychother.: Forsch. Prax."},{"key":"10.1016\/j.euroneuro.2013.01.001_bib48","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1162\/105474601300343603","article-title":"The experience of presence: factor analytic insights","volume":"10","author":"Schubert","year":"2001","journal-title":"Presence"},{"key":"10.1016\/j.euroneuro.2013.01.001_bib49","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4088\/JCP.v66n0420b","article-title":"Efficacy of quetiapine in generalized social anxiety disorder: results from an open-label study","volume":"66","author":"Schutters","year":"2005","journal-title":"J. Clin. Psychiatry"},{"issue":"Suppl. 20","key":"10.1016\/j.euroneuro.2013.01.001_bib50","first-page":"S22","article-title":"The Mini International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.01.001_bib51","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1192\/bjp.132.2.133","article-title":"Catechol-O-methyl transferase activity in patients with depressive illness and anxiety states","volume":"132","author":"Shulman","year":"1978","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.01.001_bib52","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3389\/fpsyt.2012.00082","article-title":"Quetiapine and buspirone both elevate cortical levels of noradrenaline and dopamine in vivo, but do not have synergistic effects","volume":"3","author":"Silverstone","year":"2012","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.01.001_bib53","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/hup.1256","article-title":"Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo-controlled studies","volume":"26","author":"Stein","year":"2011","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2013.01.001_bib54","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0005-7916(94)00072-T","article-title":"Fear of spiders questionnaire","volume":"26","author":"Szymanski","year":"1995","journal-title":"J. Behav. Ther. Exp. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.01.001_bib55","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.pnpbp.2007.06.027","article-title":"Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study","volume":"31","author":"Vaishnavi","year":"2007","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2013.01.001_bib56","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/00004714-200204000-00016","article-title":"The anxiolytic effect of the novel antipsychotic ziprasidone compared with diazepam in subjects anxious before dental surgery","volume":"22","author":"Wilner","year":"2002","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2013.01.001_bib57","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.euroneuro.2011.07.018","article-title":"The size and burden of mental disorders and other disorders of the brain in Europe 2010","volume":"21","author":"Wittchen","year":"2011","journal-title":"Eur. Neuropsychopharmacol."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X13000035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X13000035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T03:21:55Z","timestamp":1539919315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X13000035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":57,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0924977X13000035"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2013.01.001","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute anxiolytic effects of quetiapine during virtual reality exposure\u2014A double-blind placebo-controlled trial in patients with specific phobia","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2013.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}